| Frio Pharmaceuticals |
| Phyllis B. Siegel CEO |
| http://friopharma.com/ |
| Bio |
| Drugs for Oral Health |
| Frio Pharmaceuticals Inc. is dedicated to oral-systemic health. Frio Pharmaceuticals Inc was spun out of Biomedical Development Corporation (BDC), its research affiliate, in 1999 to manufacture and sell a dental waterline cleaner. This platform technology has evolved into a robust pipeline of pharmaceuticals to treat oral diseases and interrupt the disease process. BDC (parent company) will assign the technology to Frio Pharmaceuticals (recipient).
Frio is uniquely positioned to be the best product to answer the unmet needs of patients, dentists, and insurance companies. Oral systemic health is an emerging market with no recognized leader. Frio is developing a pipeline of pharmaceuticals to lead this market.
The goal of this project is to commercialize a broad-spectrum antimicrobial platform technology, with the first products being: (1) a pharmaceutical to treat thrush (oral candidiasis) in cancer patients with thrush and (2) a pharmaceutical to treat gingivitis (oral inflammation). |
